



Triphase Accelerator Corporation Announces New Collaboration with Celgene Corporation

-- New Agreement Provides Option for Celgene to
Acquire New Bi-Specific Antibody Licensed by Triphase --

Toronto and San Diego, October 28, 2014 -- Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced a new strategic collaboration with Celgene Corporation. The new agreement provides Celgene with the option to acquire a novel bi-specific antibody that Triphase licensed from PharmAbcine. The bi-specific antibody targets VEGFR-2/TIE 2 and is currently in preclinical studies.

"We have made important progress in our existing collaboration with Celgene, and now expand the collaboration with the addition of a bi-specific antibody," said Frank Stonebanks, founder, president and CEO of Triphase. "This option agreement and collaboration with Celgene provides us with the resources to study a novel drug and explore the potential to make a meaningful difference in the treatment of cancer with high unmet medical needs."

Under the new agreement, Triphase received an upfront payment and will control product development and retain all commercial rights to the bi-specific antibody. If Celgene exercises its option to acquire the antibody from Triphase, Celgene will become responsible for product development and retain commercial rights, and Triphase will be eligible to receive regulatory and sales milestone payments if Celgene exercises its option to acquire the antibody.

"We have been pleased with the efficient and clear progress made by Triphase within our existing collaboration," said George Golumbeski, Ph.D., senior vice president, business development for Celgene Corporation. "We look forward to a second collaboration with Triphase that will focus on a molecule that has produced exciting preclinical data."

About Triphase

Triphase is a private drug development company with a primary focus on oncology and operations in San Diego and Toronto. Triphase is dedicated to advancing novel compounds through Phase II proof-of-concept clinical studies using a unique, science-based, high-quality model that is faster and more cost-effective than traditional pharmaceutical and biotech industry drug development approaches. Triphase was spun out of the Ontario Institute for Cancer Research (OICR) and MaRS Innovation, and has a strategic relationship with Celgene for oncology-focused drug development opportunities. For more information, visit www.triphaseco.com or LinkedIn.

Media Contact:

Julie Normart

BrewLife

jnormart@w2ogroup.com

415-946-1087

###